Contineum Therapeutics, Inc. financial data

Symbol
CTNM on Nasdaq
Industry
Pharmaceutical Preparations
Location
3565 General Atomics Court, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.96K %
Debt-to-equity 5.64 %
Return On Equity -30.7 % +4.69%
Return On Assets -21.8 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.9M shares
Common Stock, Shares, Outstanding 2.38M shares
Entity Public Float 356M USD
Common Stock, Value, Issued 2K USD
Weighted Average Number of Shares Outstanding, Basic 19.4M shares +738%
Weighted Average Number of Shares Outstanding, Diluted 19.4M shares +470%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 38.4M USD +39.2%
General and Administrative Expense 12.5M USD +97.3%
Operating Income (Loss) -50.9M USD -417%
Nonoperating Income (Expense) 8.64M USD +21.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -42.3M USD -282%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -42.3M USD -286%
Earnings Per Share, Basic -2.18 USD/shares -260%
Earnings Per Share, Diluted -0.4 USD/shares +85.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.9M USD +41.3%
Marketable Securities, Current 183M USD +66.7%
Cash, Cash Equivalents, and Short-term Investments 205M USD
Assets, Current 206M USD +61.6%
Property, Plant and Equipment, Net 989K USD +45.9%
Operating Lease, Right-of-Use Asset 5.47M USD +660%
Other Assets, Noncurrent 3K USD -99.8%
Assets 213M USD +63.2%
Accounts Payable, Current 1.81M USD +185%
Employee-related Liabilities, Current 3.34M USD +75.3%
Accrued Liabilities, Current 6.71M USD +53%
Liabilities, Current 9.97M USD +81.9%
Operating Lease, Liability, Noncurrent 4.81M USD +4351%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 14.8M USD +159%
Accumulated Other Comprehensive Income (Loss), Net of Tax 71K USD -34.3%
Retained Earnings (Accumulated Deficit) -117M USD -56.2%
Stockholders' Equity Attributable to Parent 198M USD
Liabilities and Equity 213M USD +63.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.98M USD -52.1%
Net Cash Provided by (Used in) Financing Activities -18K USD +97.1%
Net Cash Provided by (Used in) Investing Activities 8.73M USD -6.67%
Common Stock, Shares Authorized 39.6M shares 0%
Common Stock, Shares, Issued 2.38M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 738K USD -78.9%
Deferred Tax Assets, Valuation Allowance 35.5M USD +40.4%
Deferred Tax Assets, Gross 36.8M USD +44%
Operating Lease, Liability 6.26M USD +994%
Payments to Acquire Property, Plant, and Equipment 147K USD +183%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -42.3M USD -285%
Property, Plant and Equipment, Gross 2.71M USD +25.6%
Operating Lease, Liability, Current 1.45M USD +213%
Deferred Tax Assets, Operating Loss Carryforwards 14.5M USD +15.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 3.09M USD +20.2%
Additional Paid in Capital 315M USD +4343%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 61K USD -16.4%
Deferred Tax Assets, Net of Valuation Allowance 1.29M USD +412%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%